Bullish Or Bearish For X4 Pharmaceuticals Inc (NASDAQ: XFOR) In 2024

X4 Pharmaceuticals Inc (NASDAQ:XFOR) shares, rose in value, with the stock price up by 6.52% to the previous day’s close as strong demand from buyers drove the stock to $1.47.

Actively observing the price movement in the last trading, the stock closed the session at $1.38. The value of beta (5-year monthly) was 0.44. Referring to stock’s 52-week performance, its high was $2.58, and the low was $0.57. On the whole, XFOR has fluctuated by 51.02% over the past month.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


With the market capitalization of X4 Pharmaceuticals Inc currently standing at about $246.87 million, investors are eagerly awaiting this quarter’s results, scheduled for May 02, 2024 – May 06, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.16, which is expected to increase to $0.36 for fiscal year -$0.47 and then to about -$0.45 by fiscal year 2025. Data indicates that the EPS growth is expected to be 17.50% in 2025, while the next year’s EPS growth is forecast to be 4.30%.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that XFOR’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium term indicators have put the stock in the category of 50% Buy while long term indicators on average have been pointing out that it is a 50% Buy.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of XFOR currently trading nearly 31.94% and 50.76% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 73.77, while the 7-day volatility ratio is showing 10.02% which for the 30-day chart, stands at 10.54%. Furthermore, X4 Pharmaceuticals Inc (XFOR)’s beta value is 0.46, and its average true range (ATR) is 0.12.

A comparison of X4 Pharmaceuticals Inc (XFOR) with its peers suggests the former has fared considerably weaker in the market. XFOR showed an intraday change of 6.52% in last session, and over the past year, it grew by 68.97%%.

Data on historical trading for X4 Pharmaceuticals Inc (NASDAQ:XFOR) indicates that the trading volumes over the past 10 days have averaged 5.36 million and over the past 3 months, they’ve averaged 2.01 million. According to company’s latest data on outstanding shares, there are 167.43 million shares outstanding.

Nearly 27.41% of X4 Pharmaceuticals Inc’s shares belong to company insiders and institutional investors own 35.96% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 14.22 million shares as on Mar 15, 2024, resulting in a short ratio of 9.06. According to the data, the short interest in X4 Pharmaceuticals Inc (XFOR) stood at 8.49% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 13.23 million. The stock has risen by 75.31% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the XFOR stock heading into the next quarter.